



## COVID-19 Vaccination in Hemodialysis Patients Correspondence

Rujittika Mungmunpantipantip<sup>1</sup> · Viroj Wiwanitkit<sup>2</sup>

Received: 3 January 2022 / Accepted: 24 February 2022 / Published online: 8 March 2022  
© Italian Society of Hypertension 2022

Dear Editor,

We would like to share ideas on “Humoral Immune Response to COVID-19 Vaccination in Hemodialysis Patients: A Retrospective, Observational Case-Control Pilot Study [1]”. Piscitani et al. noted that “This study supports the finding of hyporesponsiveness to mRNA vaccination among hemodialysis patients [1]”. The impact of COVID-19 vaccination on immunocompromised recipients is an interesting topic of research right now. In the event of hemodialysis, a reduced immune response is likely, which could influence the immune response to vaccination. Background immunological status could be a key factor influencing responsiveness [2]. An evaluation of the hemodialysis patient's immune function before vaccination could provide important information for determining the vaccine's effectiveness. Nevertheless, the impact of COVID-19 vaccine type should be considered. There is a difference in immunological response after immunization with different types of vaccines, according to a recent study [3].

**Authors contributions** RM 50 %—(1a) Substantial contributions to study conception and design. (1b) Substantial contributions to acquisition of data. (1c) Substantial contributions to analysis and interpretation of data. (2) Drafting the article or revising it critically for important intellectual content. (3) Final approval of the version of the article to be published. VW 50 %—(1a) Substantial contributions to study

conception and design. (1b) Substantial contributions to acquisition of data. (1c) Substantial contributions to analysis and interpretation of data. (2) Drafting the article or revising it critically for important intellectual content. (3) Final approval of the version of the article to be published

### Declarations

**Conflict of interest** The authors declare that they have no competing interest.

### References

1. Piscitani L, Del Pinto R, Basili A, Tunno M, Ferri C. Humoral immune response to COVID-19 vaccination in hemodialysis patients: a retrospective, observational case-control pilot study. *High Blood Press Cardiovasc Prev.* 2022. <https://doi.org/10.1007/s40292-021-00502-5> (**Online ahead of print**).
2. Duni A, Markopoulos GS, Mallioras I, Pappas H, Pappas E, Koutlas V, Tzalavra E, Baxevanos G, Priska S, Gartzonika K, Mitsis M, Dounousi E. The humoral immune response to BNT162b2 vaccine is associated with circulating CD19+ B lymphocytes and the naive CD45RA to memory CD45RO CD4+ T helper cells ratio in hemodialysis patients and kidney transplant recipients. *Front Immunol.* 2021;12:760249.
3. Ionita C, Marcelli D, Nita C, Anton C, Berca S, Vacar S, Schiller O, Gheorghiu C, Barth C. Comparison of antibody response to two different mRNA Covid-19 vaccines in patients on hemodialysis. *J Nephrol.* 2022. <https://doi.org/10.1007/s40620-021-01195-8> (**Online ahead of print**).

✉ Rujittika Mungmunpantipantip  
rujittika@gmail.com

<sup>1</sup> Bangkok, Thailand

<sup>2</sup> Dr DY Patil University, Pune, India